8-K filed June 18, 2024, 7:59 PM ET ticker SHPH CIK 0001757499

leadership confidence high sentiment neutral materiality 0.55

Shuttle Pharma names Timothy Lorber as CFO; Vander Hoek shifts to VP Regulatory

Shuttle Pharmaceuticals Holdings, Inc.

Timothy Lorber, CPA with 40+ years experience, appointed CFO; part-time until Sept 9, 2024, then full-time from Sept 10, 2024.
Lorber receives $227k annual base salary; 227,635 RSUs vesting over 3 years; eligible for up to $72k milestone bonus.
Current CFO Michael Vander Hoek transitions to full-time Vice President, Regulatory concurrent with Lorber's full-time appointment.
Vander Hoek had served as both CFO and VP Regulatory for past four years; will now focus on regulatory matters for Phase 2 trial.

item 5.02 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-24-024224
form_type: 8-K
ticker: SHPH
cik: 0001757499
company_name: Shuttle Pharmaceuticals Holdings, Inc.
filed_at: 2024-06-18T23:59:59+00:00
discovered_at: 2026-05-14T18:03:19.917227+00:00
generated_at: 2026-06-01T03:56:11.956699+00:00
sec_items: ["5.02", "8.01", "9.01"]
event_type: leadership
sentiment: neutral
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-24-024224
json_url: https://secwatch.observer/filing/0001493152-24-024224.json
markdown_url: https://secwatch.observer/filing/0001493152-24-024224.md
text_url: https://secwatch.observer/filing/0001493152-24-024224.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Timothy J. Lorber

Chief Financial Officer

SHPH · Shuttle Pharmaceuticals Holdings, Inc.

Effective: 2024-06-13
Filed: June 18, 2024, 7:59 PM ET

On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.

Role change

Michael Vander Hoek

Vice President, Regulatory

SHPH · Shuttle Pharmaceuticals Holdings, Inc.

Effective: 2024-09-10
Successor: Timothy J. Lorber
Filed: June 18, 2024, 7:59 PM ET

The Company’s current Chief Financial Officer, Mr. Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and, effective September 10, 2024, will assume the Vice President, Regulatory position on a full-time basis.

Source-grounded claims

8fa0a96d9d

Timothy J. Lorber was appointed as Chief Financial Officer at Shuttle Pharmaceuticals Holdings, Inc..

On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

9315dc2132

Michael Vander Hoek changed role as Vice President, Regulatory at Shuttle Pharmaceuticals Holdings, Inc..

The Company’s current Chief Financial Officer, Mr. Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and, effective September 10, 2024, will assume the Vice President, Regulatory position on a full-time basis.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Comparable filings

GRAL

GRAIL appoints Joshua Ofman as CEO with amended compensation and severance

GRAIL, Inc. June 1, 2026, 4:07 PM ET leadership Items 5.02, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02, 8.01, 9.01 same event type: leadership similar materiality

This filing

On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.

Comparable filing

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers In connection with Dr. Joshua Ofman’s appointment as the Chief Executive Officer of GRAIL, Inc. (the “Company”), on June 1, 2026, the Company’s board of directors (the “Board”) approved an amended and restated offer letter (the “Amended Offer Letter”) and authorized and directed the Company to enter into such Amended Offer Letter with Dr. Ofman, with the Amended Offer Letter effective as of June 1, 2026 (the “Effective Date”).

Filing page SEC filing

ARQ

Arq appoints Shimon Steinmetz as CFO, CAO Stacia Hansen resigns

Arq, Inc. May 27, 2026, 4:32 PM ET leadership Items 5.02, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02, 8.01, 9.01 same event type: leadership similar materiality

This filing

On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.

Comparable filing

On May 20, 2026, Stacia Hansen, the Chief Accounting Officer and Treasurer of the Company, submitted her resignation and the Board accepted such resignation. The effective date of Ms. Hansen's resignation as Chief Accounting Officer is expected to be June 12, 2026.

Filing page SEC filing

CRVL

CorVel CEO Michael Combs to become Executive Chair; Sarah Scott appointed CEO and President effective July 1, 2026

CORVEL CORP June 1, 2026, 5:05 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.

Comparable filing

In connection with the leadership transition, the Board appointed Sarah Scott to serve as Chief Executive Officer and President of the Company, effective July 1, 2026.

Filing page SEC filing

WTTR

Select Water Solutions COO Skarke moves to Chief Commercial Officer; no successor named

Select Water Solutions, Inc. June 1, 2026, 5:00 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.

Comparable filing

Effective June 1, 2026, Michael C. Skarke transitioned from serving as the Executive Vice President and Chief Operating Officer of Select Water Solutions, Inc. (the “Company”) to serving as the Company’s Executive Vice President and Chief Commercial Officer,

Filing page SEC filing

TTD

The Trade Desk appoints Nate Olmstead as CFO effective July 9, 2026; interim CFO Davis resumes CAO role

Trade Desk, Inc. June 1, 2026, 4:35 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.

Comparable filing

On June 1, 2026, The Trade Desk, Inc. (the “Company”) announced the appointment of Nate Olmstead, age 54, as the Company’s chief financial officer.

Filing page SEC filing

WST

West Pharmaceutical appoints Michel Lagarde as CEO; Green retires, Friel becomes Chair

WEST PHARMACEUTICAL SERVICES INC June 1, 2026, 4:32 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.

Comparable filing

As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.

Filing page SEC filing

LPX

LP Building Solutions announces CFO succession: Alan Haughie to retire; Aaron Howald named CFO effective Sept 1, 2026

LOUISIANA-PACIFIC CORP June 1, 2026, 4:31 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.

Comparable filing

On May 27, 2026, Alan J.M. Haughie, Executive Vice President and Chief Financial Officer of Louisiana-Pacific Corporation (“LP”, the “Company”), notified the Board of Directors of LP (the “Board”) of his intention to retire from the role of Executive Vice President and Chief Financial Officer, effective September 1, 2026.

Filing page SEC filing

PENG

Penguin Solutions CFO Nate Olmstead to step down; Aaron Johnson named interim CFO; reaffirms FY2026 guidance at high end

Penguin Solutions, Inc. June 1, 2026, 4:17 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.

Comparable filing

On May 31, 2026, the board of directors of the Company appointed Aaron Johnson, the Company’s Vice President, Finance and Accounting, as interim CFO and as the Company’s principal financial and accounting officer, succeeding Mr. Olmstead in these positions effective as of July 9, 2026, on an interim basis until the Company appoints a successor.

Filing page SEC filing

Source: SEC EDGAR

accession 0001493152-24-024224

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.